Identifying Prostate Brachytherapy Seeds Using MRI

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01878058

Enrollment

Registered

2013-06-14

Start date

2012-10-31

Completion date

2016-08-31

Last updated

2016-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer Patients Who Have Brachytherapy Seed Implant

Keywords

Prostate cancer, Brachytherapy, Seed implant

Brief summary

This study will look at the feasibility of using a type of Magnetic Resonance Imaging called Susceptibility Weighted Imaging (SWI) to detect your implanted radioactive seeds. Researchers hope that using SWI will eliminate the need to use CT imaging to detect your implanted radioactive seeds. This study will also see if the MRI seed detection is as effective as current standard practice of seed detection (routine MRI and CT imaging). This technique would be beneficial for brachytherapy without the need to fuse the MRI and CT images, as is done currently.

Interventions

OTHERMRI Scan

Patient will receive an additional MRI scan in addition to their standard of care imaging

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. At least 18 years old 2. Histologic diagnosis of adenocarcinoma of the prostate 3. No contraindications for Pelvic body MRI 4. Patients undergoing LDR brachytherapy at PMH and scheduled for post implant analysis with CT-MR (standard at PMH) 5. Ability to provide written informed consent to participate in the study

Exclusion criteria

1. Contraindication for Pelvic body MRI 2. Patient not willing/consenting for this study

Design outcomes

Primary

Measure	Time frame
Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce registration errors	6 months
Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will reduce planning time for the post-implant plan	6 months
Determine if using the MR scan -(SWI) used to detect the implanted radioactive seeds will eliminate the CT scan of the patient.	6 months

Secondary

Measure	Time frame	Description
Compare the differences in MR seed identification using the MR pulse sequence vs. CT images.	6 months	Our goal is to perfectly match these two modalities with acceptance test of 97%. This technique would be beneficial for LDR (Low Dose Rate) Brachytherapy without need to fuse the CT and MR images and eliminate any image registration uncertainly.

Other

Measure	Time frame
Compare the prostate dosimetry (V100 and D90) in prostate low dose rate therapy using MR alone with CT/MR fusion.	6 months

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026